Sorrento Therapeutics Inc (SRNE): "Sorrento intends to develop the lead MP...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	57
Posts	5700
Boards Moderated	0
Alias Born	12/13/2004

dia76ca

Re: None

Thursday, 08/26/2021 3:52:18 PM

Thursday, August 26, 2021 3:52:18 PM

"Sorrento intends to develop the lead MPro inhibitor(MP18) in oral administration form and as a component of an antiviral cocktail therapy to potentially eliminate current and emerging coronavirus infections."
Could the antiviral cocktail be a combination of oral MP18 and oral Salicyn-30?
This could be very powerful and combined with oral Abivertinib and nasal COVIDROPS.
Sorrento's Covid portfolio is synergistic ! Very impressive !

"The refusal of the real is the number one dogma of our time" Rene Girard

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent SRNE News

Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM